Bluebird reports 17 people with sickle cell disease started receiving Lyfgenia gene therapy, with 35 starting Zynteglo for ...

which was developed by Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics (CRSP). In late September, bluebird announced it was cutting its workforce by 25% as part of a restructuring initiative ...

Shares in bluebird ticked up following the announcement. Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.

In this article, we are going to take a look at where bluebird bio, Inc. (NASDAQ:BLUE) stands against other most promising gene editing stocks to buy according to hedge funds. The pharmaceutical ...

With a rich background in finance and experience in the pharmaceutical sector, including roles at bluebird bio and Jubilant Pharma, Krawtschuk is expected to bring valuable insight to Eagle’s ...

bluebird bio's Zynteglo has become the first ... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.

Eagle Pharmaceuticals (EGRX) announced the appointment of Christopher ... Most recently, Mr. Krawtschuk served as CFO and Treasurer of bluebird bio. Published first on TheFly – the ultimate source for ...

BEAM-101 seems to be competitive with approved sickle cell treatments, William Blair analysts said in a note to investors, ...

bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today reported third quarter results and business highlights for the quarter ended September 30, 2024, including recent commercial ...

Bluebird priced the treatment at a considerable ... One of the more challenging endeavors investors in biotech and pharma face is estimating peak sales. Professional analysts are at times ...

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.